ANYSEALS
Board
2 directors, 1 in day-to-day management, 1 auditor, last change in January 2026Director and managing director
director since 01-01-2018
managing director appointed by deed of 15-05-2018
6-year term from 2026
listed in the 2025 annual accounts, filed on 13-07-2026
Director
since 01-03-2022
6-year term from 2026
listed in the 2025 annual accounts, filed on 13-07-2026
Mandates through the years
3 names, the dashed line is todayDirector, Managing director
Director
Statutory auditor
LeadershipBoardRest of the termmandate already running before its first mention
Mandates as a list
-
- Director, from 01-01-2018 to date
- Managing director, appointed by deed of 15-05-2018, still in office
-
- Director, since before 31-12-2021
-
- Statutory auditor, appointed by deed of 07-08-2014, still in office
With Starter you also see 7 former office holders in the mandate history.
See the plans →
Control
consolidates
This company
ANYSEALS
Equity €13.8m
Profit €6.4m in 2025
Capital
- Capital
- €2,000,000
- Shares
- 203,170 in the 2025 annual accounts
- Contribution per share
- €9.84
- Equity per share
- €68.00 in 2025
- Source
- deed of 08-08-2024
Owners through the years
as the annual accounts name themSource: parent in its own accounts
Capital transactions
Shareholders according to the deeds
After the capital increase
deed of 07-09-2012 ↗
- 87,073 shares · €1,500,000 in kind
Stated in the deed
deed of 07-09-2012 ↗
After the capital increase
deed of 02-02-2011 ↗
- €1,640,000 in kind
Stated in the deed
deed of 02-02-2011 ↗
- 26,667 shares
Stated in the deed
deed of 29-01-2010 ↗
Capital over time
- 08-08-2024 Capital stated in the deed · €2,000,000 · 203,170 shares
- 07-09-2012 Capital increase of €1,500,000 · to €3,500,000 · 87,073 new shares, 42.9% of the 203,170 shares after the increase
- 07-09-2012 Capital reduction of €1,500,000 · to €2,000,000 · “amortisatie van verliezen”
- 02-02-2011 Capital increase of €1,640,000 · to €7,140,000 · 26,667 new shares at €61.50 per share · in kind
- 02-02-2011 Capital reduction of €5,140,000 · to €2,000,000 · “amortisatie van de verliezen aangegeven in de recent afgesloten balans”
- 29-01-2010 Capital increase of €2,000,000 · to €5,500,000 · 32,520 new shares · “inbreng schuldvordering”